238 related articles for article (PubMed ID: 25144562)
21. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
22. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
23. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT.
Samarin A; Hüllner M; Queiroz MA; Stolzmann P; Burger IA; von Schulthess G; Veit-Haibach P
Nucl Med Commun; 2015 Dec; 36(12):1165-73. PubMed ID: 26397999
[TBL] [Abstract][Full Text] [Related]
25. Neurolymphomatosis: a single-center experience of neuromuscular manifestations, treatments, and outcomes.
Jeong J; Kim SW; Sung DH
J Neurol; 2021 Mar; 268(3):851-859. PubMed ID: 33098033
[TBL] [Abstract][Full Text] [Related]
26. FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomes.
Davidson T; Kedmi M; Avigdor A; Komisar O; Chikman B; Lidar M; Goshen E; Tzila Zwas S; Ben-Haim S
Leuk Lymphoma; 2018 Feb; 59(2):348-356. PubMed ID: 28750592
[TBL] [Abstract][Full Text] [Related]
27. (18)F-FDG PET-CT: a powerful tool for the diagnosis and treatment of relapsing polychondritis.
Lei W; Zeng H; Zeng DX; Zhang B; Zhu YH; Jiang JH; Huang JA
Br J Radiol; 2016; 89(1057):20150695. PubMed ID: 26529231
[TBL] [Abstract][Full Text] [Related]
28. The value of 18F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis.
Vali R; Punnett A; Bajno L; Moineddin R; Shammas A
Pediatr Transplant; 2015 Dec; 19(8):932-9. PubMed ID: 26515450
[TBL] [Abstract][Full Text] [Related]
29. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up using 18F-FDG PET/CT for postoperative olfactory neuroblastoma.
Fujioka T; Toriihara A; Kubota K; Machida Y; Nakamura S; Kishimoto S; Ohashi I; Shibuya H
Nucl Med Commun; 2014 Aug; 35(8):857-63. PubMed ID: 24751700
[TBL] [Abstract][Full Text] [Related]
31. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
Kumar R; Hawkins RA; Yeh BM; Wang ZJ
Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.
Ulaner GA; Goldman DA; Sauter CS; Migliacci J; Lilienstein J; Gönen M; Schöder H; Moskowitz CH; Zelenetz AD
Radiology; 2015 Nov; 277(2):518-26. PubMed ID: 26035588
[TBL] [Abstract][Full Text] [Related]
33. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
[TBL] [Abstract][Full Text] [Related]
34. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT?
Schaarschmidt BM; Grueneisen J; Heusch P; Gomez B; Umutlu L; Ruhlmann V; Rosenbaum-Krumme S; Antoch G; Buchbender C
Nucl Med Commun; 2015 Jun; 36(6):588-95. PubMed ID: 25759944
[TBL] [Abstract][Full Text] [Related]
35. MRI and FDG PET/CT findings of hepatic epithelioid hemangioendothelioma.
Dong A; Dong H; Wang Y; Gong J; Lu J; Zuo C
Clin Nucl Med; 2013 Feb; 38(2):e66-73. PubMed ID: 22996250
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.
Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R
Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633
[TBL] [Abstract][Full Text] [Related]
37. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
38. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
40. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
